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Abstract
Background: The fatality attributed to pandemic influenza A H1N1 was not clear in the literature. We described the
predictors for fatality related to pandemic influenza A H1N1 infection among hospitalized adult patients.
Methods: This is a multicenter study performed during the pandemic influenza A H1N1 [A(H1N1)pdm09] outbreak
which occurred in 2009 and 2010. Analysis was performed among laboratory confirmed patients. Multivariate
analysis was performed for the predictors of fatality.
Results: In the second wave of the pandemic, 848 adult patients were hospitalized because of suspected influenza,
45 out of 848 (5.3%) died, with 75% of fatalities occurring within the first 2 weeks of hospitalization. Among the 241
laboratory confirmed A(H1N1)pdm09 patients, the case fatality rate was 9%. In a multivariate logistic regression
model that was performed for the fatalities within 14 days after admission, early use of neuraminidase inhibitors
was found to be protective (Odds ratio: 0.17, confidence interval: 0.03-0.77, p = 0.022), nosocomial infections (OR:
5.7, CI: 1.84-18, p = 0.013), presence of malignant disease (OR: 3.8, CI: 0.66-22.01, p = 0.133) significantly increased
the likelihood of fatality.
Conclusions: Early detection of the infection, allowing opportunity for the early use of neuraminidase inhibitors,
was found to be important for prevention of fatality. Nosocomial bacterial infections and underlying malignant
diseases increased the rate of fatality.
Background
In April 2009 a novel strain of human influenza A of
swine origin, identified as A(H1N1)pdm09 virus, rapidly
spread worldwide, and in early June 2009 the World
Health Organization (WHO) raised the pandemic alert
level to phase 6 [1]. Many northern countries experienced
the first wave of outbreak during late spring and summer
months, followed by an early 2009 fall influenza season
[2]. The first laboratory confirmed case in Istanbul was
reported in May 2009 [3]. According to the Ministry of
Health of Turkey, approximately 6.5 million people were
infected, 13,000 patients were hospitalized, and 656 per-
sons died due to the 2009 pandemic H1N1 infection.
It was important to describe the clinical picture and
define the risk factors of A(H1N1)pdm09 infection, in
order to support public health policy makers in developing
vaccination strategies, antiviral use, and other control
measures [4]. The clinical and epidemiologic characteris-
tics of the patients hospitalized because of A (H1N1)
pdm09 infection were described in the beginning of the
outbreak [2,4-7]. However, detailed studies to understand
the course of the disease and the predictors of fatality are
necessary for a description of such a historical outbreak.
Herein, we describe the predictors of fatality among adult
hospitalized patients due to A (H1N1) pdm09 infection in
Istanbul, Turkey. Description of the clinical features of
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hospitalized patients in Istanbul, a city with the population




The study was performed by the İstanbul Pandemic
influenza study group of The Turkish Society of Clinical
Microbiology and Infectious Diseases (KLIMIK). During
and after the 2009 Pandemic, all available data of the
hospitalized patients in Istanbul were included in the
study. The largest 11 hospitals of Istanbul participated
in the study. Three of these hospitals were University
Hospitals, and eight were training and research hospi-
tals of The Ministry of Health of Turkey. All patients
hospitalized with suspected A (H1N1) pdm09 infection
who were ≥ 14 years of age were included in the study.
In the beginning of the outbreak, all suspected imported
cases were hospitalized for the purpose of disease con-
tainment regardless of their need for medical support.
Accordingly, these imported cases of the first wave of
the outbreak were excluded from this study. The patients
from the second wave of the outbreak that started in the
beginning of September 2009 were hospitalized because
of clinical signs and symptoms of the A (H1N1) pdm09
infections.
The laboratory confirmation was performed by the
rRT-PCR method provided by the CDC, Atlanta in one
of the two National Influenza Reference Laboratories
located in the Istanbul Faculty of Medicine, and at the
laboratories of one university and one military hospital.
Among the hospitalized patients laboratory diagnosis
confirmed patients were included in the study. Infectious
diseases and clinical microbiology specialists collected
data electronically in individual hospitals, and the pooled
data were analyzed. The hospital, official administrative
and laboratory data were also reviewed for the consistency
of the data related to Istanbul. The study was approved by
the Medical Ethics Committee of Marmara University
Medical Faculty as a non-interventional clinical research
with the number of 09.2010.0097.
Statistical analysis
In univariate analysis, for comparing fatal and survived
cases, categorical data were tested by chi square test and t
test was used for comparison of the means of two groups
(Tables 1 and 2). Parameters found to be statistically
significant in univariate analyse, were tested by logistic
regression to predict the risk of fatality (Table 3). The
independent variables included in the model were early
use of neuraminidase inhibitors, nosocomial infection,
and having a malignant disease. In analysis STATA (USA,
Texas, version 11) was used, with statistical significance
set as <0.05.
Results
The first cases of Pandemic Influenza A (H1N1) were
recorded in May 2009 and the last cases were seen in
February 2010. The patients hospitalized during the
second wave of the outbreak, which started in September
were included in the study (Figure 1). In the second wave
of the infection, 848 patients suspected of A (H1N1)
pdm09 were hospitalized. Among the hospitalized patients,
9% were admitted to the intensive care unit and 45 (5.3%)
Table 1 Demographic characteristics of the laboratory
confirmed A (H1N1) pdm09 infected cases and their risk
factors for fatality
Fatal
n = 22 (%)
Survived
n = 219 (%)
p
Female gender 10 (45) 143 (65) 0.065
Mean age 37 (sd 17) 35 (sd 16) 0.543
Age ≥ 65 2 (9) 17 (8) 0.826
Morbid Obesity 1 (5) 14 (6) 0.732
Pregnant women 1 (10) 50 (35) 0.105
Comorbid chronic diseases 11 (50) 89 (41) 0.396
Chronic heart disease 3 (14) 24 (11) 0.704
Diabetes mellitus 1 (5) 18 (8) 0.542
Chronic renal disease 2 (9) 11 (5) 0.421
Chronic neurologic disease 2 (9) 11 (5) 0.421
Chronic obstructive lung
disease
3 (14) 21 (10) 0.546
Malignancy 3 (14) 5 (2) 0.005
Vaccinated against H1N1 0 3 (0.37) 0.675
Laboratory findings
Leukocyte count, median 13, 875 8,700 0.046
Thrombocyte count, median 132,000 180,500 0.074
AST, median 59 25 <0.001
ALT, median 65 21 0.004
CPK, median 285 92 0.005
LDH, median 675 248 0.001
C reactive protein, median 31 25 0.135
Table 2 Pulmonary findings of the patients
Fatal
n = 22 (%)
Survived
n = 219 (%)
p
Abnormal auscultation of the lung 13 (59) 79 (36) 0.034
Bilateral involvement in chest x-ray 18/20 (90) 59/147 (40) <0.001
Type of involvement in chest x-ray
Lobar 1/14 (7) 15/137 (11) 0.608
Interstitial 11/17 (65) 52/137 (38) 0.034
Diffuse consolidation 5/16 (31) 20/136 (15) 0.091
Effusion 3/17 (18) 2/134 (1) <0.001
Need for mechanic ventilation 15 (68) 13 (6) <0.001
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died. We limited our analysis with the 241 A(H1N1)
pdm09 laboratory confirmed patients (Figure 1). Among
241 laboratory confirmed influenza A(H1N1)pdm09
patients, 22 (9%) died. Nineteen out of 22 fatal cases
(86%) were in ICU, whereas 13 out of 219 (6%) survived
cases were in ICU (p < 0.001).
All the co-morbid chronic diseases were more common
among the fatal cases, but particularly fatality was more
commonly observed among patients with malignancies
(Table 1). The proportion of pregnant women among
female patients was 33%. Out of 51 pregnant women 1
(2%) died, and the fatality rate among pregnant women
was less than the non-pregnant women (9%). However,
this difference was not statistically significant (p = 0.105).
The proportion of the patients with a body mass index >
30, or clinically judged as obese, among fatal and sur-
vived cases were found to be similar (p = 0.732). The most
common symptoms among H1N1 confirmed patients
were fever (89%), cough (87%), shortness of breath (59%),
myalgia (56%), headache (54%), sore throat (52%), and
diarrhea (10%).
Leukocyte and thrombocyte counts were lower in the
fatal group compared to the surviving patients. The median
alanine transferase, aspartate transferase, lactate dehydro-
genase, creatinin phosphokinase, and C reactive protein
levels were higher among fatal cases (Table 1). Pulmonary
findings were common among fatal cases (Table 2).
Among laboratory confirmed influenza A(H1N1)pdm09
cases, the median length of stay was 5 days (interquartile
range 2 and 9). Secondary nosocomial bacterial infection
was detected in 18 out of 241 (7%) patients. The most
commonly isolated nosocomial bacterial pathogens were
Acinetobacter spp. (n = 4), Methicillin resistant Staphylo-
coccus spp. (n = 4), E.coli (n = 3), Pseudomonas spp. (n = 1),
and Klebsiella spp. (n = 1).
Out of 241 laboratory confirmed patients, 222 (93%)
received oseltamivir, and 4 (2%) received zanamivir. Among
the patients who used neurominidase inhibitors within
48 hours after onset of symptoms the case fatality rate
was 2%, whereas among the patients who did not use
the CFR it was 13%. Among the hospitalized patients
with confirmed diagnosis of H1N1 infection, 69% received
at least one antibiotic. In decreasing order, 67 patients
(28%) received respiratory quinolones, 64 patients (26%)
received macrolides, 35 (15%) third generation cephalo-
sporins, 40 (16%) ampicillin with sulbactam or amoxicillin
with clavulanic acid, 25 (10%) carbapenems, 14 (6%)
piperacillin-tazobactam. The rate of vaccination against
H1N1 was 0.4, whereas against seasonal flu was 7%.
In multivariate logistic regression, early use of neuramin-
idase inhibitors was found to be protective (Odds ratio:
0.17, confidence interval: 0.03-0.77, p = 0.022), nosocomial
infections (OR: 5.7, CI: 1.84-18, p = 0.013), presence of ma-
lignant disease (OR: 3.8, CI: 0.66-22.01, p = 0.133) (Table 3).
Table 3 Univariate and multivariate analyses for the predictors of the fatality
Univariate analysis Multivariate analysis
Odds ratio Confidence interval p Odds ratio Confidence interval P
Using neuraminidase inhibitors within
two days after onset of symptoms
0.33 0.14-0.79 0.13 0.17 0.03-0.77 0.022
Nosocomial infection 10 4.9-23.2 <0.001 5.7 1.84-18 0.013
Presence of malignancy 4.5 1.6-12.4 0.003 3.8 0.66-22.01 0.133
First wave
May-August 2009
259 cases with no fatality
Second wave
September 2009 -February 2010
853 cases with 47 fatality
H3N2 cases
5 cases with 2 fatality (40%)
H1N1 suspected cases 
848 cases with 45 fatality (5.3%)
Clinical diagnosis only
607 cases with 4% fatality
Laboratory confirmed cases
241 H1N1 cases with 9% fatality
Figure 1 Hospitalized patients with suspected A(H1N1)pdm09 infection in Istanbul between May 2009 and February 2010.
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Discussion
Istanbul has a population of 13 million according to the
2011 census. Analysis of the pandemic influenza data of
Istanbul is valuable because Istanbul has high population
and has a potential of being an entrance gate for pan-
demic infections. Turkey experienced the first wave of
the outbreak from May to August, followed by an early
2009 fall influenza season. Usually the influenza season
in Turkey starts in December. The majority of the patients
in the first wave were imported cases. Since these patients
were hospitalized in order to contain the pandemic, their
data was not included in this study. The first cases of the
second wave were reported between September 2009 and
February 2010. Since almost all cases were detected as
H1N1 infection in this period, the Ministry of Health of
Turkey declared that it was not necessary to confirm the
laboratory diagnosis for hospitalized cases. On the other
hand, the strongest feature of this study was inclusion of
almost all the patients who were hospitalized because of
H1N1 in Istanbul. Since the largest state hospitals partici-
pated in the study, the goal of presenting a realistic picture
of the first pandemic of the 21st century was achieved.
In our study, the mean ages of fatal and survived cases
were not statistically different. The fatality rate among
the patients over 65 years of age were not found to be
higher, although many authors reported that being older
than 65 years of age was associated with fatality [8].
According to a systematic analysis which included 44
articles on A (H1N1) pdm09, early in the pandemic the
disease occurred overwhelmingly in children and youn-
ger adults, and the case fatality rate was 2.9% among
confirmed patients [9]. In a study from the USA, which
included hospitalized patients, which included also chil-
dren [10], among 255 hospitalized patients 8% died. In
our study, the case fatality rate was 9.1% among the
confirmed cases. The majority of the fatalities (75%)
occurred within the first 2 weeks of hospitalization.
Thirteen percent of confirmed patients were admitted
to the intensive care unit. In another multicenter study
performed in Turkey, a total of 821 children with 2009
pandemic H1N1 were hospitalized. The majority of
admitted children (56.9%) were younger than 5 y of
age, and 35 children (4.3%) died. The death rate was
significantly higher in patients with malignancy, chronic
neurological disease, immunosuppressive therapy, at least
1 pre-existing condition, or respiratory complications [11].
Cough and fever were the most common clinical symp-
toms as it was reported for the confirmed cases in previous
reports [9]. Nosocomial bacterial infection was detected in
7% of the patients. In one study it was reported that bac-
terial co-infection was common and was associated with
age > 50 years and co-morbidities [12]. As one of the dif-
ferent features from seasonal influenza, A (H1N1) pdm09
was reported to pose an increased risk of severe illness in
pregnant women [10,13-15]. On the other hand, some
studies reported no increased risk of fatality because of A
(H1N1) pdm09 infection among the pregnant women
[16,17]. In our study group, the proportion of the preg-
nant women among female patients was 33%, and the case
fatality proportion was lower in pregnant women than the
non-pregnant women. Because of the awareness about the
higher fatality among pregnant women, hospitalization
was high. Severely obese individuals with and without
chronic conditions were reported to be at increased risk
for respiratory hospitalizations during influenza seasons
[10,18-20]. However, in our study the proportion of obese
patients with body mass index of >30 or clinically judged,
among fatal and survived cases were found to be similar
(p = 0.912, Table 1). Lack of association of obesity and
pregnancy with fatality could be related to low power of
the study.
Early use of oseltamivir was reported to be beneficial
in treatment [8,10,21,22]. Furthermore, it was reported
that among the patients with A(H1N1)pdm09 infection,
early use of antiviral therapy prevented development
of pneumonia [23,24]. We found that the patients who
received neuraminidase inhibitors within 2 days after
the disease onset were found to be less likely to die in
comparison with the patients who received neuramin-
idase inhibitors later than two days (Odds ratio: 0.16,
confidence interval: 0.03-0.74, p = 0.019, Table 3). Ac-
cording to a recent study from USA, chest radiographs
obtained at hospital admission revealed pneumonia in
103 (46%) of 255 patients. Among 255 hospitalized patients,
208 (82%) received neuraminidase inhibitors, but only 47%
had treatment ≤ 2 days after illness onset [10]. The rate of
vaccination against A (H1N1) pdm09 was 0.4 and was
much lower than the rate of vaccination against seasonal
flu. Unnecessary use of antibiotics was common among
patients who were hospitalized for A (H1N1) pdm09.
One of the reasons for such a high rate of unnecessary
antibiotic use was obtaining the A (H1N1) pdm09 test
results requires an average of 2–3 days. Early diagnosis
of influenza virus infection will decrease unnecessary
use of antibiotics.
Conclusion
In Influenza A (H1N1) pdm09 infection, using neuramin-
idase inhibitors within 2 days after onset of symptoms
decreased, whereas nosocomial bacterial infections and
underlying malignant diseases increased CFR.
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